For patients with advanced NSCLC, assessing the presence of drug-sensitive EGFR mutations is a critical step in disease management as third-generation EGFR-TKIs are the standard-of-care first-line treatment for advanced EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.